---
title: "AstraZeneca, Daiichi Sankyo Breast Cancer Drug Wins NHS Access in England"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299243970.md"
description: "Women in England with an aggressive form of breast cancer will get access to an AstraZeneca Plc and Daiichi Sankyo Co. drug on the National Health Service after an agreement with the regulator, according to Bloomberg."
datetime: "2026-09-16T23:15:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299243970.md)
  - [en](https://longbridge.com/en/news/299243970.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299243970.md)
generator: "portal-rs"
---

# AstraZeneca, Daiichi Sankyo Breast Cancer Drug Wins NHS Access in England

Women in England with an aggressive form of breast cancer will get access to an AstraZeneca Plc and Daiichi Sankyo Co. drug on the National Health Service after an agreement with the regulator, according to Bloomberg.

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [DSNKY.US](https://longbridge.com/en/quote/DSNKY.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [4568.JP](https://longbridge.com/en/quote/4568.JP.md)

## Related News & Research

- [Key facts: AstraZeneca (AZN) NICE OK Enhertu; FDA review; China plan](https://longbridge.com/en/news/299411391.md)
- [AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England](https://longbridge.com/en/news/299312441.md)
- [AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective](https://longbridge.com/en/news/298875452.md)
- [AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears](https://longbridge.com/en/news/298828016.md)
- [Cellectis pivots to in vivo gene editing, restructures operations to extend cash runway into H2 2028](https://longbridge.com/en/news/298875964.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**